Glenmark Pharmaceuticals shines after ANDA approval
DSIJ Intelligence / 10 Apr 2017
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Fenofibrate Capsules.
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (USFDA) for Fenofibrate Capsules. The capsules USP, 67 mg, 134 mg and 200 mg are the generic version of Tricor Micronized Capsules, 67 mg, 134 mg and 200 mg of AbbVie Inc.
According to IMS Health's sales data for the 12-month period ending February 2017, the Tricor Micronized Capsules, 67 mg, 134 mg and 200 mg have achieved annual sales of approximately USD 97.5 million (Rs 628 crore).
Glenmark Pharmaceuticals’ current portfolio consists of 114 products authorised for distribution in the US marketplace. Approximately 64 ANDAs of the company are pending for approval with the USFDA. At the same time, it continues to identify and explore external development partnerships for supplementing and accelerating the growth of its existing pipeline and portfolio.
The stock price of Glenmark Pharmaceuticals increased 1.19 per cent in early trade, and is trading at Rs 867.4 on an intraday basis.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.